Day One Biopharmaceuticals Hits 52-Week High Amid $2.5 Billion Servier Acquisition Deal

Day One Biopharmaceuticals (DAWN) shares surged to a new 52-week high of $21.48 following the announcement of its acquisition by Servier. The French pharmaceutical giant, Servier, has agreed to acquire the company in an all-cash deal valued at approximately $2.5 billion, or $21.50 per share. This acquisition comes after a period of exceptional performance for DAWN, with the stock gaining over 130% since the beginning of the year and more than 200% over the past 12 months. Despite the positive momentum, several analysts have downgraded the stock to "Neutral" or "Hold" ratings. This shift in sentiment reflects the fact that the current market price is now closely aligned with the agreed buyout price, leaving limited room for further appreciation. The deal underscores the ongoing consolidation within the biotechnology sector as major players seek to expand their portfolios through strategic acquisitions.